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ABSTRACT
Sorafenib, a tyrosine kinase inhibitor, has been demonstrated to exert anti-tumor 
effects. However, the molecular mechanisms underlying its effects on bladder cancer 
remain unknown. 
Here, we evaluated the mechanisms responsible for the sorafenib-induced anti-
tumor effects on 5637 and T24 bladder cancer cells. We demonstrated that sorafenib 
reduces cell viability, stimulates lysosome permeabilization and induces apoptosis 
of bladder cancer cells. These effects are dependent by the activation of cathepsin 
B released from lysosomes. The sorafenib-increased cathepsin B activity induced 
the proteolysis of Bid into tBid that stimulates the intrinsic pathway of apoptosis 
characterized by mitochondrial membrane depolarization, oxygen radical generation 
and cytochrome c release. Moreover, we found that cathepsin B enzymatic activity, 
induced by sorafenib, is dependent on its dephosphorylation via PTEN activation and 
Akt inactivation. Pretreatment with orthovanadate rescued bladder cancer cells from 
apoptosis. In addition, the Akt inhibitor perifosine increased the sensitivity of bladder 
cancer cells to sorafenib-induced cytotoxicity. 
Overall, our results show that apoptotic cell death induced by sorafenib in bladder 
cancer cells is dependent on cathepsin B activity and involved PTEN and Akt signaling 
pathways. The Akt inhibitor perifosine increased the cytotoxic effects of sorafenib in 
bladder cancer cells. 
INTRODUCTION
Sorafenib is an oral multi-target inhibitor of the Raf-
1 and B-Raf kinases, which are members of the Raf/MEK/
ERK signaling pathway. In bladder cancer (BC) cells, 
sorafenib has been found to induce apoptosis, however 
the cellular and molecular mechanisms responsible 
for the anti-tumor effects in BC cells remain at present 
unknown [1]. Sorafenib has been found to inhibit several 
receptor tyrosine kinases (RTKs) that are involved in neo-
angiogenesis and tumor progression, such as vascular 
endothelial growth factor receptors (VEGFR1-3), platelet-
derived growth factor receptors (PDGFR a and b), tyrosine 
protein kinase Kit (c-kit), fms-related tyrosine kinase 3 
(Flt3), Colony stimulating factor 1 receptor (CSF-1R) 
and Rearranged during Transfection (RET) [2]. In vivo, 
sorafenib has been administered in phase II clinical trials 
to patients with urothelial carcinoma (UC) who had been 
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treated with one prior chemotherapy regimen [3] and to 
patients with metastatic UC [4]. In addition, sorafenib 
has been administered in combination with cisplatin and 
gemcitabine to patients with node-negative transitional BC 
cells [5], but no objective responses have been detected 
to date. Chemotherapy of bladder cancers represents the 
mainstay of treatment and confers survival advantage. 
However, despite such advances, it remains disappointing 
because of its toxicity, reinforcing again the rationale for 
the discovery of new targeted therapeutic approaches [6]. 
The phosphoinositide 3-kinase/protein kinase 
B (PI3-K/Akt) pathway, frequently altered in BC, 
plays a key role in the regulation of cell proliferation, 
angiogenesis and cell survival and represents a potential 
therapeutic target [7,8]. In addition to targeting RTKs, 
sorafenib also affects the PI3-K/Akt pathways and their 
negative regulator, the lipid phosphatase and tensin 
homolog (PTEN) pathway. The activation of PI3K/Akt 
signaling mediates the acquired resistance to sorafenib 
in hepatocellular carcinoma (HCC) cells [9]; PTEN over-
expression enhances the sensitivity of HCC cells to the 
anti-proliferative and pro-apoptotic effects of sorafenib 
[10]. Akt is up-regulated in many human cancers, 
including BC. Approximately 21% of muscle-invasive 
BCs exhibit activating PI3K/Akt mutations, and another 
30% display evidence of PTEN inactivation [11,12]. 
Stimulation of the PI3K/Akt/PTEN signaling pathway 
via aberrant RTK activity, which occurs by the reversible 
alteration of the phosphorylation state of specific tyrosine 
residues, results in the impairment of cell survival/
proliferative responses [13,14]. The RTK-mediated 
activation of PI3K increases the phosphatidylinositol 
3,4,5 phosphate (PIP3) levels, leading to Akt activation 
[15]. The lipid phosphatase PTEN acts as a negative 
regulator of the PI3K/Akt pathway by dephosphorylating 
PIP3. Phosphorylated PTEN is unable to associate with 
the membrane due to a conformational change and, hence, 
does not inhibit PI3K signaling [16]. The balance between 
PTEN and PI3K signaling modulates the basal PIP3 levels 
in the plasma membrane, which, in turn, regulates cell 
survival and proliferation [16].
Lysosomes and cathepsins play a major role in 
tumor cell death [17,18]. The lysosome permeabilization 
or rupture, facilitates cathepsin release, causing cell 
death via mitochondria-dependent apoptosis [19,20]. 
Among lysosomal enzymes, cathepsin B (CB) is a 
cysteine protease primarily involved in the degradation or 
processing of lysosomal proteins [21], as well as vesicle 
trafficking [22], inflammasome generation [23] and cell 
death [24].
In the present study, we found that sorafenib induces 
apoptosis of BC cells via the activation and inactivation of 
PTEN and Akt pathways, respectively, thereby stimulating 
CB activity and Bid fragmentation, which induced 
the mitochondrial-dependent pathway of apoptosis. In 
addition, in the view to reduce the sorafenib-mediated side 
effects and to maintain the efficiency of drug treatment, 
our findings provided a rationale for the use of the Akt 
inhibitor perifosine as an adjuvant with sorafenib in 
clinical trials of advanced BC. 
RESULTS
Sorafenib inhibits the survival and induces 
apoptosis in BC cells
The ability of sorafenib to inhibit the viability of the 
5637 and T24 BC cell lines was evaluated through dose-
response (2.5, 10 and 20 µM) (Fig. 1A) and time-course 
(24, 48 and 72 h) (Fig. 1B) analysis. Sorafenib inhibited 
the growth of BC cells at 24 h after treatment, with IC50 
values of 11.57 µM and 11.58 µM for 5637 and T24 BC 
cells, respectively. 
Then we investigated by FITC-conjugated Annexin 
V (Ann V-FITC/PI) staining and flow cytometric analysis, 
the ability of sorafenib to induce apoptosis of BC. We 
found that sorafenib at 10 µM and 20 µM (Supplementary 
Figure 1) induces dose-dependent apoptosis of both 5637 
and T24 BC cells, with 20 µM showing higher apoptotic 
effects compared with dose 10 µM; the 20 µM sorafenib-
induced effect started at 12 h (% apoptotic cells: 52% and 
62% in 5637 and T24 BC cells, respectively) and was 
maximal at 24 h after treatment (% apoptotic cells: 60% 
and 78% in 5637 and T24 BC cells, respectively) (Fig. 1C 
and supplementary Fig S1). 
Sorafenib induces lysosome permeabilization, 
cathepsin B (CB) release and activation in BC 
cells
Several studies have suggested a close association 
between lysosomal function and apoptosis [25]. Moreover, 
CB has been demonstrated to be one of the major 
lysosomal cysteine proteases that plays an important role 
in apoptosis [26]. Thus, the integrity of lysosome in BC 
cells, treated with sorafenib, was evaluated by Lysotracker 
Green staining and cytofluorimetric analysis. Lysotracker 
was added to BC cells treated for 1 and 2 h with sorafenib, 
and green fluorescence was investigated using the FL1 
channel. We found that, due to loss of lysosome integrity, 
sorafenib mainly reduces the green fluorescence at 1 h 
after treatment of about 50% and 30% in T24 and 5637 
BC cells, respectively (Fig. 2A). Then, to further address 
the release of lysosomal CB into the cytosol of BC cells, 
a cytosolic extract from BC cells treated for different 
times (1, 3 and 6 h) with sorafenib, obtained eliminating 
cytosolic organelles by ultracentrifugation, was analyzed 
by immunoblotting. We observed that in sorafenib-treated 
BC cells, the CB level increases in a time-dependent 
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manner; it starts at 1 h and is maximal at 6 h after 
treatment (Fig 2B). 
In addition, we investigated, by using whole cell 
lysates, the ability of sorafenib to trigger CB activation 
and enzymatic activity in BC cells. We found that 
sorafenib treatment increases CB activation at 1 h after 
treatment by stimulating the cleavage of the immature 
CB pro-peptide (p37) to generate its active form (p25) 
(Fig. 2C). Moreover, by the use of the fluorogenic peptide 
Z-Arg-Arg-AMC we also found that sorafenib enhances 
CB activity in a time-dependent manner; CB activity was 
evidenced at 1 h and peaks at 6 h after treatment (Fig. 2D). 
Overall, these results evidenced that sorafenib induces 
lysosome leakage, CB release, activation and enzymatic 
activity in BC cells.
CB directly interacts with sorafenib
We demonstrated the feasibility of a molecular 
interaction between CB and sorafenib and by performing 
molecular modeling of the docking site of the potential 
CB/sorafenib complex. The analysis of molecular docking 
between CB and sorafenib revealed complete insertion of 
this drug into the catalytic groove of CB, covering the 
active site (Cys29, His199 and Asn219). In particular, 
sorafenib bound to CB with a strong affinity (0.54 nM), 
forming a complex displaying a total intermolecular 
energy of -95.35 kcal/mol (EVdW = -77.87 kcal/mol; EElect 
= -17.48 kcal/mol) (Fig. 3 A, B). Notably, this predicted 
affinity is equivalent to that of the physiological inhibitor 
cystatin C (0.6nM) [27]. Specifically, the CB/sorafenib 
complex contained 6 H-bonds established via the amino 
acids His111, Cys119, Glu122, Gly198 and Trp221 (mean 
length of 2.23Å) that contribute to complex stabilization, 
along with electrostatic and van der Waals forces. As for 
the interaction between CB and other TKIs [28], CB binds 
to pazopanib with an affinity of 13.49 nM, thus forming a 
complex displaying a total intermolecular energy of -85.20 
kcal/mol (EVdW = -79.14 kcal/mol; EElect = -6.06 kcal/mol) 
(Supplementary Fig. 2 A, B). Collectively, the results of 
Figure 1: Sorafenib reduces the 5637 and T24 cell viability and induces apoptotic cell death. A) Cell growth was evaluated 
by MTT assay in 5637 and T24 cells treated with different doses of sorafenib (2.5, 10, 20 µM) for 24 h. Data shown are the mean ± SD of 
three independent experiments. **p<0.01, sorafenib- vs vehicle-treated cells. IC50 value was determined as concentration exerting a half-
maximal inhibition of cell growth. B) Cell growth was evaluated by MTT assay in 5637 and BC T24 cells treated with sorafenib (20 µM) 
for different times (24, 48 and 72 h). Data shown are the mean ± SD of three independent experiments. **p<0.01, vs vehicle-treated cells. 
C) 5637 and T24 cells treated with sorafenib 20 µM or with vehicle for 24 h were stained with Ann V-FITC and analyzed by FACS. One 
representative experiment out of three independent experiments is shown.
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Figure 2: Sorafenib induces lysosome permeabilization and CB activation. A) Lysosome leakage was evaluated in BC cells 
treated with sorafenib (20 µM) or vehicle for 1 and 2h by lysotracker staining. One representative experiment out of three independent 
experiments is shown. B) Representative blots of cytosol extracts from BC cells treated with sorafenib (20 µM) for different times or with 
vehicle for 1h probed using an anti-CB Ab. The GAPDH expression levels were used as a loading control. The densitometric data are 
expressed as the mean ± SD of three independent experiments. **p<0.01 vs vehicle-treated cells; ##p<0.01 vs 1 h of treatment; §§p<0.01 vs 
3 h of treatment. No statistical significant difference was found between untreated and vehicle-treated cells or comparing different times 
of vehicle-treatment each other (data not shown). C) Lysates from 5637 and T24 cells treated for 1h with sorafenib (20 µM) or vehicle 
were separated via 12% SDS-PAGE and probed using an anti-CB Ab. The GAPDH expression levels were used as a loading control. One 
representative experiment is shown. The densitometric data are expressed as the mean ± SD of three independent experiments. **p<0.01 
vs vehicle-treated cells. No statistical significant difference was found between untreated and vehicle-treated cells (data not shown). D) 
CB activity was measured in 5637 and T24 cells treated for different periods with sorafenib (20 µM) or for 1 h with vehicle using the 
fluorogenic peptide Z-Arg-Arg-AMC and a SpectraMax Gemini XPS microplate reader. The presented data are expressed as the means 
± SD of three independent experiments. **p<0.01 vs vehicle-treated cells; ##p<0.01 vs 1, 3 or 12 h of treatment. No statistical significant 
difference was found between untreated and vehicle-treated cells or comparing different times of vehicle-treatment each other (data not 
shown).
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molecular modeling and the comparative analysis with 
pazopanib strongly suggest that there is a direct interaction 
between CB and sorafenib that forms a stable complex. 
Sorafenib, through CB activation, induces Bid 
activation that triggers the intrinsic pathway of 
apoptosis in BC cells
CB has been found to activate the conversion of 
Bid to its active form tBid and consequently to trigger the 
intrinsic pathway of apoptosis [29]. Thus, the effect of 
sorafenib on Bid activation was evaluated. We found that 
treatment with sorafenib (20 μM) for 6 and 12 h induces 
the cleavage of the pro-apoptotic Bid protein to generate 
the truncated form tBid, resulting in a reduction in Bid 
(p22) expression and a parallel increase in tBid (p15) 
expression (Fig. 4A). This effect was markedly reverted 
at 6 h after sorafenib treatment by the CB inhibitor, 
CA074Me used at 2.5 μM (Fig. 4B) and 5 μM (data not 
shown). Next, the involvement of mitochondria and ROS 
generation in the sorafenib-induced apoptosis of BC 
cells was evaluated via JC-1 and DCFDA staining and 
FACS analysis. We found that sorafenib induces a time-
dependent decrease in ΔΨm and a parallel increase in 
ROS production in both types of BC cells. Mitochondrial 
depolarization was detected approximately at 8 h and 
peaking at 24 h after treatment (89.8% in 5637 cells; 
82.6% in T24 BC cells) (Fig. 4C). We also observed that 
sorafenib stimulates ROS generation that peaks at 8 h 
and declines at the later time point (Fig. 4D). In addition, 
by western blot analysis of sorafenib-treated cytosol 
extracts of BC cells, we found that sorafenib induces 
the translocation of cytochrome c from the mitochondria 
to the cytosol of BC cells (Fig. 4E). Finally, we further 
examined the caspase-dependence of sorafenib-induced 
apoptosis. Thus, the BC cells were treated for 12 h with 
10 µM (Fig. 4E) and 50 µM (data not shown) of the pan-
caspase inhibitor, the ZVAD-fmk peptide alone or in 
combination with sorafenib. A significant reduction in the 
percentage of apoptotic Ann V+ cells was detected in BC 
cells treated with sorafenib (20 μM) and ZVAD-fmk (10, 
50 μM) compared with those cells treated with sorafenib 
alone (Fig. 4F). 
Collectively, these results indicate that, sorafenib, 
activating CB, stimulates BID cleavage and promotes 
the activation of the mitochondrial-dependent intrinsic 
pathway of apoptosis in BC cells.
Role of PTEN in sorafenib-induced CB activation 
in BC cells
Sorafenib has been shown to activate various 
PTPs in different cell types [14,30-32]. Herein, the 
effect of sorafenib on SHP-1 and/or PTEN activation 
was evaluated in BC cells via western blot analysis. We 
found that although SHP-1 is expressed in T24 BC cells, 
sorafenib does not induce SHP-1 phosphorylation at any 
time point after sorafenib treatment (Supplementary Fig. 
3). In addition, sorafenib significantly increased PTEN 
phosphatase activity in a time-dependent manner, as 
shown by the increase in the non-phosphorylated PTEN 
levels in T24 cells. PTEN dephosphorylation was initially 
detected at 15 min, progressively increasing until 1 h and 
slightly decreasing at 2 h after sorafenib treatment (Fig. 
Figure 3: The catalytic groove of CB interacts with sorafenib. A) Sorafenib docks in the catalytic groove of CB (represented with 
protein surface) and covers the active site. The predicted equilibrium dissociation constant (Kd,pred) of the sorafenib/CB complex compared 
with that of pazopanib/CB is shown in the box. B) Cys29 and the other amino acids of CB involved in H-bond formation with the drug are 
indicated. 
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Figure 4: Sorafenib induces BID cleavage and mitochondrial-dependent apoptosis in 5637 and T24 BC cells. A) Lysates 
from 5637 and T24 cells treated for 6 or 12 h with sorafenib (20 µM) or for 6 h with vehicle were separated via 12% SDS-PAGE and probed 
using an anti-Bid or anti-GAPDH Abs. One representative experiment out of three independent experiments is shown. The densitometric 
data are expressed as the mean ± SD of three independent experiments. **p<0.01 vs vehicle-treated cells; ##p<0.01 vs 6 h of treatment. No 
statistical significant difference was found between untreated and vehicle-treated cells or comparing different times of vehicle-treatment 
each other (data not shown). B) Lysates from 5637 and T24 cells treated for 6 h with sorafenib (20 µM) alone or in combination with 
CA074Me were separated via 12% SDS-PAGE and probed using an anti-Bid or anti-GAPDH Abs. One representative experiment is 
shown. The densitometric data are expressed as the mean ± SD of three independent experiments. **p<0.01 vs sorafenib-treated cells. 
C) ΔΨm changes on 5637 and T24 BC cells, treated with sorafenib (20 µM) or vehicle, was evaluated at different times by JC-1 staining 
and biparametric FL1(green)/FL2(red) flow cytometric analysis. Data represent one out of three separate experiments. Numbers are the 
percentage of cells showing a drop of ΔΨm related fluorescence intensity. D) ROS production was evaluated in 5637 and T24 BC cells 
treated for different periods with sorafenib (20 µM) or vehicle via DCFDA staining and FACS analysis. The data are presented as the mean 
± SD of three independent experiments and are expressed as the fold-change relative to the vehicle-treated cell. **p<0.01 vs vehicle-treated 
cells; ##p<0.01 vs 4, 12 or 24 h of treatment. E) Cytosolic extracts from 5637 and T24 BC cells treated for 6 h with sorafenib (20 µM) or 
vehicle were separated via 12% SDS-PAGE and probed using an anti-cytochrome c Ab. The GAPDH expression levels were used as a 
loading control. One representative experiment out of three independent experiments is shown. F) 5637 and T24 BC cells treated for 12 h 
with sorafenib (20 µM) alone or in combination with (10 µM) Z-VAD-FMK were stained with Ann V-FITC and analyzed via FACS. The 
data are expressed as the percentages of positive cells ± SD based on three separate experiments. **p<0.01 vs vehicle-treated cells; ##p<0.01 
vs sorafenib-treated cells.
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5A). No changes in the total PTEN protein levels were 
detected in the sorafenib-treated T24 BC cells. Similar 
results were obtained using 5637 BC cells (data not 
shown). Pretreatment of BC cells with 0.25 mM (Fig. 5B) 
and 0.50 mM (data not shown) of the specific tyrosine-
phosphatase inhibitor, orthovanadate for 30 min prior to 
treatment with sorafenib (20 μM) strongly reduced at 12 h 
after treatment, the percentage of sorafenib-induced Ann 
V+ apoptotic cells, as evaluated by FACS analysis (Fig. 
5B). 
Recent report showed that the increase of CB 
activity is related to its rapid tyrosine-dephosphorylation 
[33]. Thus, the ability of sorafenib to reduce CB 
tyrosine phosphorylation levels was evaluated. Based 
on immunoprecipitation and western blot analyses using 
anti-pTyr and anti-CB Abs, we demonstrated that in BC 
cells, CB is tyrosine phosphorylated at a basal level and 
that treatment with sorafenib decreases the CB tyrosine 
phosphorylation levels in a time-dependent manner (% 
of decrease: 60% and 75% at 1 h and 3 h, respectively) 
(Fig. 5C). Moreover, pretreatment of sorafenib-treated BC 
cells with orthovanadate markedly reduced CB activity in 
a time-dependent manner (Fig. 5D). Similar results were 
obtained using 5637 BC cells (data not shown). Taken 
together, these data indicate that sorafenib increases CB 
activity by inducing CB tyrosine dephosphorylation and 
this effect is likely mediated by PTEN activation.
Sorafenib suppresses Akt tyrosine kinase activity 
by promoting Akt degradation in BC cells
PTEN is a negative regulator of Akt activity [16] 
and sorafenib has been found to induce PTEN activation. 
Figure 5: Sorafenib stimulates CB dephosphorylation and PTEN activity in T24 BC cells. A) Lysates from T24 cells 
treated with sorafenib (20 µM) for 15, 60 and 120 min or with vehicle for 15 min were separated via 9% SDS-PAGE and probed using 
anti-non-phospho-PTEN, anti-PTEN and anti-GAPDH Abs. One representative experiment is shown. The densitometric data are expressed 
as the mean ± SD of three separate experiments. **p<0.01 vs vehicle-treated cells. No statistical significant difference was found between 
untreated and vehicle-treated cells or comparing different times of vehicle-treatment each other (data not shown). B) T24 BC cells treated 
for 12 h with sorafenib (20 µM), alone or in combination with orthovanadate (Na3VO4, 0.25 mM) were stained with Ann V-FITC and 
analyzed via FACS. The data are expressed as the percentage of positive cells and are presented as the means ± SD of three independent 
experiments. **p<0.01 vs vehicle-treated cells; ##p<0.01 vs sorafenib-treated cells. C) Cell lysates from T24 BC cells either untreated or 
treated with sorafenib (20 µM) for 1 or 3 h were immunoprecipitated (IP) using a monoclonal anti-CB Ab. The immunoprecipitates were 
separated via 12% SDS-PAGE and then immunoblotted (IB) using Abs against phospho-tyrosine (anti-pTyr) and CB. The lysates were also 
immunoprecipitated using isotype-matched IgG, which was used as a control. One representative experiment is shown. The densitometric 
data are expressed as the mean ± SD of three separate experiments. **p <0.01 vs untreated cells; ##p<0.01 vs 1 h of treatment. D) CB 
activity was measured in T24 BC cells treated for different periods with vehicle or sorafenib (20 µM) either alone or in combination with 
orthovanadate (Na3VO4, 0.25 mM). The data are presented as the means ± SD of three independent experiments. **p<0.01 vs vehicle-
treated cells; ##p<0.01 vs sorafenib-treated cells. Data shown are relative to T24 cell line and are representative of BC lines analyzed.
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Thus, the ability of sorafenib to reduce the Akt tyrosine 
phosphorylation levels in T24 BC cells was evaluated. 
Based on western blot analysis, we demonstrated that 
sorafenib inhibits Akt phosphorylation in T24 BC cells 
in a time-dependent manner (Fig. 6A). The inhibition of 
phosphor-Akt expression paralleled that of the total Akt 
protein, indicating that in T24 BC cells, sorafenib acts 
inducing a time-dependent down-regulation of the Akt 
protein (Fig. 6A). Then, we further examined the ability 
of perifosine, a specific inhibitor of Akt phosphorylation, 
to inhibit CB tyrosine phosphorylation in T24 BC cells. 
We showed that at 3 h after treatment, perifosine markedly 
reduces the basal CB tyrosine phosphorylation levels in 
a dose-dependent manner (Fig. 6B). Similar results were 
obtained using 5637 BC cells (data not shown). Finally, 
to elucidate the mechanism of Akt down-regulation, BC 
cells were treated for 6 h with sorafenib in the presence 
of 50 nM (Fig. 6C) and 100 nM (data not shown) of the 
lysosome inhibitor, bafylomycin A (Fig. 6C). We found 
that bafylomycin A completely blocks sorafenib-induced 
Figure 6: Sorafenib induces degradation of the Akt protein in T24 BC cells. A) In the representative immunoblots lysates 
from T24 cells treated with sorafenib (20 µM) for different times or with vehicle for 1h were probed using anti-phospho-Akt, anti-Akt and 
anti-GAPDH Abs. The densitometric data are expressed as the mean ± SD of three separate experiments. **p<0.01 vs vehicle-treated cells; 
##p<0.01 vs 1 h of treatment; §§p<0.01 vs 3 h of treatment. No statistical significant difference was found between untreated and vehicle-
treated cells or comparing different times of vehicle-treatment each other (data not shown). B) Cell lysates from T24 cells treated for 3h 
with vehicle or perifosine (0.5, 1 or 2.5 µM) were immunoprecipitated (IP) using a monoclonal anti-CB Ab. The immunoprecipitates were 
separated via 12% SDS-PAGE and then immunoblotted (IB) using Abs against phospho-tyrosine (pTyr) and CB. The lysates were also 
immunoprecipitated using isotype-matched IgG, which was used as a control. One representative experiment is shown. The densitometric 
data are expressed as the mean ± SD of three separate experiments. **p <0.01 vs vehicle-treated cells; ##p<0.01 vs 0.5 µM of perifosine. No 
statistical significant difference was found between untreated and vehicle-treated cells (data not shown). C) Lysates from T24 cells treated 
for 6 h with vehicle or sorafenib (20 µM) and bafilomycin A1 (50 nM) alone or in combination were separated via 9% SDS-PAGE and 
probed using anti-Akt or anti-GAPDH Abs. One representative experiment is shown. The densitometric data are expressed as the mean ± 
SD of three separate experiments. **p<0.01 vs vehicle-treated cells; ##p<0.01 vs sorafenib-treated cells. No statistical significant difference 
was found between untreated and vehicle-treated cells or comparing different vehicles-treatment each other (data not shown). Data shown 
are relative to T24 cell line and are representative of BC lines analyzed.
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Akt protein degradation. Treatment with the lysosome 
inhibitor in the absence of sorafenib did not induce any 
significant effect (Fig. 6C). Similar results were obtained 
using the 5637 BC cells (data not shown).
The Akt inhibitor perifosine sensitizes BC cells to 
sorafenib-induced apoptotic cell death
Recent data have indicated that sorafenib in 
combination with perifosine induces mitochondria-
mediated cell death and anti-tumor effects in NOD/SCID 
mice xenografted with a Hodgkin lymphoma cell line [34]. 
However, neither in vitro nor in vivo findings on the effects 
of sorafenib administered in combination with perifosine 
has been reported in BC cells to date. Thus, we evaluated 
the effects of different doses of perifosine (0.5, 1.0 or 2.5 
μM) alone and in combination with sorafenib (10 and 20 
μM) in T24 BC cells. We found that perifosine reduces 
the viability of T24 BC cells in a dose-dependent manner 
at 24 h, showing a maximal effect (42.1% of inhibition) 
with the 2.5 μM dose (Fig. 7A). By standard isobologram 
and CompuSyn software analysis we evaluated the 
combination index (CI) and we found that the combination 
of sorafenib 10 or 20 µM with perifosine at the doses 1 and 
2.5 µM shows synergistic effect increasing the cytotoxicity 
against T24 BC cells (Fig. 7B). Moreover, the use of 
sorafenib at 10 μM in combination with perifosine at 
different doses (1.0 or 2.5 μM) approximates the cytotoxic 
effects induced by sorafenib (20 µM) alone (Fig. 7B). This 
synergistic effect does not depend on the direct ability of 
perifosine to induce apoptosis (Fig. 7C), although, the 
perifosine/sorafenib combination significantly increases 
the sorafenib-induced apoptosis of BC cells (Fig. 7C). 
Thus, perifosine by inducing CB activation sensitized the 
Figure 7: Perifosine in combination with sorafenib increases the sensitivity of T24 BC cells to the sorafenib-induced 
cytotoxicity. A) Cell viability of T24 BC cells untreated or treated for 24h with sorafenib (10 and 20 µM) and perifosine (0.5, 1, 2.5 
µM) was evaluated by MTT assay. Data shown are the mean ± SD of three independent experiments. **p<0.01 vs vehicle-treated cells; 
No statistical significant difference was found between untreated and vehicles-treated cells (data not shown). For sake of simplicity only 
one vehicle sample is shown. B) The synergistic activity of sorafenib and perifosine used in combination on the viability of T24 BC cells 
was determined by the isobologram and combination index (CI) methods. The CI was used to express synergism (CI<1), additivity (CI=1) 
or antagonism (CI>1) and was calculated according to the standard isobologram equation. C) T24 BC cells treated for 24 h with sorafenib 
(10 µM) and perifosine (2.5 µM) alone or in combination, were stained with Ann V-FITC and analyzed by FACS. Data, expressed as the 
percentage of Ann V positive cells, are the mean ± SD of three separate experiments. **p<0.01 vs sorafenib-treated cells; ##p<0.01 vs 
perifosine-treated cells. Data shown are relative to T24 cell line and are representative of BC lines analyzed.
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BC cells to sorafenib-induced apoptosis. Similar results 
were obtained using the 5637 BC cells (data not shown). 
DISCUSSION
Herein, we demonstrated that sorafenib treatment 
stimulates the intrinsic pathway of apoptosis in BC cells. 
Several studies have suggested a close association between 
lysosomal function and apoptosis [25,35-38]. Anti-cancer 
agents have been reported to induce lysosome membrane 
permeabilization (LMP) [37,39-41], or rupture [25,42] 
which is followed by the release of lysosomal cathepsins. 
It has been shown that lysosomes are particularly sensitive 
toward oxidative stress [43,44]. 
Here, we demonstrated, for the first time, that the 
sorafenib-induced effects are mediated by its ability 
to stimulate the LMP leading to release of CB into the 
cytosol of BC cells. Then, BID activation and release 
of the tBid fragment [19], mitochondrial depolarization 
and cytochrome c release, ROS production and caspase 
activation are induced, resulting in the complete execution 
of the intrinsic pathway of apoptosis [17,45]. Similarly, 
in murine (MBT2 and MB49) and human T24 BC cells, 
Bacillus Calmette-Guerin induces CB activation and Bid 
fragmentation, thereby activating the intrinsic apoptotic 
pathway [29]. The effect of sorafenib treatment on 
CB activation in BC cells was further supported by a 
molecular docking analysis of the molecular interaction 
between CB and sorafenib that indicated a complete 
insertion of sorafenib into the catalytic groove of CB with 
a strong binding affinity (25-fold higher than pazopanib). 
The molecular interaction between CB and sorafenib 
results in the formation of a stable complex. In this regard, 
Cathepsins have been found to form multimolecular 
molecular complex with different molecules such us 
signaling and cytoscheleton proteins and drugs, and a 
role for these complexes in apoptotic cell death have been 
provided [46]. Thus, we can hypothesize that CB also 
binds Akt and/or PTEN, other than sorafenib, to form a 
three molecular complex permitting both PTEN and CB 
dephosphorylation and activation. In this view, recently, 
it has been found that the increase in CB activity is 
associated with its rapid tyrosine dephosphorylation [33]. 
Structural analysis of CB revealed many phosphorylation 
sites for protein kinase C or casein kinase II, as well as a 
tyrosine kinase phosphorylation site [33]. In this regard, 
based on immunoprecipitation and western blot analysis 
using anti-CB and anti-pTyr Abs, respectively, we 
confirmed not only that CB is tyrosine phosphorylated at 
a basal level, but also that sorafenib treatment significantly 
reduces the CB phosphorylation levels. Moreover, 
orthovanadate, that inhibits PTEN activation, reverts 
the sorafenib-induced apoptosis in BC cells, suggesting 
that sorafenib-induced CB tyrosine dephosphorylation 
represents a requisite to obtain the necessary CB 
enzymatic activity required to stimulate apoptosis in 
BC cells. Previous reports have indicated that sorafenib 
treatment stimulates SHP-1 and/or SHP-2 tyrosine 
phosphatase activity in breast cancer [32], glioblastoma 
[30], HCC [14] and pancreatic cancer [31] and that 
orthovanadate reduces the sorafenib-induced inhibition of 
signal transducer and activator of transcription 3 (STAT3)-
mediated tyrosine phosphorylation and increased PTP and 
SHP-2 activity in glioma cells [30]. Herein, we found that 
sorafenib significantly induces PTEN dephosphorylation, 
as evidenced by the increase in the non-phosphorylated 
form of PTEN relative to the total PTEN levels, and 
activation of its phosphatase activity [16]. Thus, the 
sorafenib-induced increase in CB activity results in 
Bid activation, thereby stimulating the apoptosis of BC 
cells. In addition, the CB dephosphorylation, might also 
occur via sorafenib-induced inhibition of Akt tyrosine 
kinase activity. In this regard, sorafenib reduces the Akt 
phosphorylation by inducing the degradation of the Akt 
protein. Pretreatment of BC cells with the lysosomal 
enzyme inhibitor bafilomycin A completely abrogated the 
sorafenib-induced Akt degradation, demonstrating that 
sorafenib acts at a post-transcriptional level by inducing 
lysosome-dependent degradation of the Akt protein [47]. 
Similarly, sorafenib has been demonstrated to promote 
the lysosomal degradation of RET protein in HEK293 
cells [48] and bafilomycin A inhibits the sorafenib-
induced degradation of ATP-binding cassette sub-family 
G member 2 transporters (ABCG2) in ABCG2-transfected 
HEK293 cells [49]. Collectively, our data demonstrated 
that sorafenib treatment by inducing PTEN activation 
and Akt inactivation/degradation, increases the CB 
dephosphorylation and enzymatic activity, thus stimulating 
BC cell apoptosis. 
Perifosine is an oral Akt inhibitor, currently 
evaluated in phase III clinical trials, shown to inhibit 
Akt and mitogen-activated protein kinase (MAPK) 
phosphorylation in prostate PC3 cells, multiple myeloma, 
HCC, glioma cells and renal carcinoma [50-54]. In 
addition in lymphoma cells, the perifosine is used in 
combination with sorafenib [34]. No data on the ability of 
perifosine to increase sorafenib-mediated cytotoxicity in 
BC cells has been reported so far. By isobologram analysis 
we found that sorafenib (10 μM) in combination with 
perifosine (2.5 μM), synergize to increase the cytotoxicity 
against T24 BC cells. The effect of sorafenib/perifosine 
drug combination in T24 BC cells, does not depend on 
the ability of perifosine to directly stimulate the apoptosis, 
but also to increase the CB activation by inducing 
dephosphorylation and activation of CB, thus sensitizing 
BC cells to sorafenib-induced apoptosis.
The knowledge of the molecular mechanisms of 
the direct anti-tumor effect of sorafenib could permit to 
identify new therapeutic targets to improve the care of 
advanced bladder cancer patients. 
Overall, in this study we demonstrated that 
activation of PTEN- and the inactivation of Akt-mediated-
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pathways by sorafenib stimulates the CB-dependent 
apoptosis of BC cells. Finally, the “dual target therapy” 
with perifosine and low dose of sorafenib in combination, 
by coupling the effects of sorafenib on PTEN and Akt 
dephosphorylation, with that induced by perifosine on CB 
dephosphorylation and activation, improves the sorafenib 
anti-tumor effects and potentially reduce the side-effects, 
thus providing a rationale for the use in clinical trials in 
patients suffering from advanced BC. 
MATERIALS AND METHODS
BC cell lines
The p53 mutant, 5637 and T24 BC cell lines, 
purchased from American Type Culture Collection 
(ATCC, Rockville, MD, USA), were maintained in RPMI-
1640 medium (Lonza Bioresearch, Basel, Switzerland) 
supplemented with 10% heat-inactivated fetal bovine 
serum, 2.5 mM N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonicacid (HEPES), 2mM L-glutamine, 100 IU/
ml of penicillin, 100 μg/ml of streptomycin (Lonza) at 
37°C, 5% CO2 and 95% humidity.
Reagents
Sorafenib was kindly provided by Bayer 
Pharmaceuticals. The following rabbit polyclonal 
antibodies (Abs) were used: anti-cytochrome C (#BV-
3026-3, Medical and Biological Laboratories, Nagoya 
City, Japan), anti-PTEN (#9559), anti-non Ser-380/Thr 
382/3836 phospho-PTEN (#9569), anti-AKT (#9227), 
anti-phospho AKT (#9271), anti-Src-homolog protein 
tyrosine phosphatase (SHP-1) (#3759) and anti-phospho 
SHP-1 (#8849) (1:1000, Cell Signalling Technology, 
Danvers, USA); anti-CB (1:250, sc-13985, Santa Cruz 
Biotechnology, Inc., Dallas, USA). The following mouse 
monoclonal Abs were used: anti-Bid (1:1000, #2002, Cell 
Signalling Technology), anti-CB (1μg/ml, IM27L, Merck 
Millipore, Darmstadt, Germany), anti-phosphotyrosine 
(anti-pTyr, 1:1000, 05-947, Merck Millipore), IgG2a 
isotype control (NBP1-96778, Novus Biologicals) 
and horseradish peroxidase (HRP)-conjugated anti-
glyceraldehyde-3-phosphate dehydrogenase (anti-
GAPDH, 1:5000, G9295, Sigma Aldrich, St. Louis, USA). 
HRP-conjugated goat anti-rabbit (1:2000, RPN4301) and 
HRP-conjugated sheep anti-mouse (1:2000, NA931V) 
were from GE Healthcare Bio-Sciences AB (Uppsala, 
Sweden). Fluorescein isothiocyanate (FITC) conjugated-
Annexin V (Ann V-FITC) was from Enzo Life Sciences 
Inc. (Farmingdale, USA). JC-1 (10 µg/mL) and 
lysotracker (50 nM) were from Invitrogen (San Diego, 
CA, USA). 2’,7’-dichlorofluorescein diacetate (DCFDA, 
10 μg/ml), dimethyl sulfoxide (DMSO, used as vehicle), 
propidium iodide (PI, 1 μg/ml), 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) and sodium 
orthovanadate (Na3VO4, 0.25 mM) were from Sigma 
Aldrich. Bafilomycin A (50 nM) was from Labogen 
S.r.l (Milan, Italy). Perifosine (0.5, 1 and 2.5 μM) was 
purchased from Selleckchem (Houston, USA), CA074Me 
(CB inhibitor, 2.5 μM, Sigma Aldrich) and Z-VAD-
FMK (caspase inhinitor, 10 μM) from Tocris Bioscience 
(Bristol, UK).
MTT assay 
The colorimetric MTT assay that measures the 
mitochondrial conversion of the tetrazolium salt to a 
blue formazan salt was used to evaluate the cell viability. 
Briefly, 5637 and T24 BC cells (3x104/ml) were seeded 
into 96-well plates and cultured with different doses of 
sorafenib (2.5, 10, 20 μM) for 24 h at 37°C, 5% CO2. In 
some experiments, cells were treated with sorafenib 20 
μM for 24, 48 and 72 h. At the end of treatment, 0.8 mg/
ml of MTT was added to the samples and incubated for 
3 h. Then the supernatants were discarded and coloured 
formazan crystals, dissolved with 100 μl/well of DMSO, 
were read by an enzyme-linked immunosorbent assay 
reader (BioTek Instruments, Winooski, USA). In 
addition, BC cells were treated with vehicle, sorafenib 
(10 μM) or with perifosine (0.5, 1 and 2.5 μM) alone or in 
combination for 24 h. Four replicates were used for each 
treatment and data were represented as the average of at 
least three separate experiments. IC50 value, representing 
the concentration exerting an half-maximal inhibition 
of cell growth, was calculated using GraphPad Prism 
Software.
The synergistic activity of sorafenib and perifosine 
used in combination on the viability of 5637 and T24 BC 
cells was determined by the isobologram and CI methods 
(CompuSin Software, ComboSyn, Inc. Paramus, NJ 
2007). The CI was used to express synergism (CI<1), 
additivity (CI=1) or antagonism (CI>1) and was calculated 
according to the standard isobologram equation [55].
Lysosome staining by LysoTracker
To investigate the involvement of lysosomes, 
BC cells were stained with LysoTracker-green. Briefly, 
5637 and T24 cells (3x105/ml), seeded into 6-well 
plates, were treated with sorafenib (20 μM) for 1 and 2 
h. Then LysoTracker-green probe (50 nM) was added for 
30 min at 37°C. Samples were analyzed by a FACScan 
cytofluorimeter using the CellQuest software; fluorescence 
intensity was expressed in arbitrary units on logarithmic 
scale. 
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Annexin V and PI staining
Apoptotic cell death on 5637 and T24 BC cells was 
evaluated using Ann V-FITC and PI staining followed 
by biparametric FACS analysis. Briefly cells, seeded as 
above described, were treated with sorafenib (10 and 20 
µM) or vehicle for different times and then incubated 
with Ann V-FITC and PI according to the manufacturer’s 
instruction. The simultaneous staining with Ann V-FITC 
and the non-vital dye PI allows the discrimination of 
intact cells (FITC-PI-), early apoptotic (FITC+PI-) and late 
apoptotic or necrotic cells (FITC+PI+). The percentage 
of positive cells determined over 10,000 events was 
analyzed on a FACScan cytofluorimeter using the 
CellQuest software. In some experiments, T24 BC cells 
were pretreated for 30 min with sodium orthovanadate 
(0.25 mM) [56] or Z-VAD-FMK (10 µM) [28] before the 
treatment with sorafenib (20 μM) for 24 h. In addition, the 
percentage of Ann V+ cells was evaluated in T24 BC cells 
treated with sorafenib (20 µM) alone or in combination 
with perifosine (2.5 µM) for 12 h.
Reactive Oxygen Species (ROS) production
5637 and T24 BC cells (4x104/ml) were seeded 
into 24-well plates and cultured for different times (4, 8 
and 12 h) with sorafenib (20 μM) or vehicle. Cells were 
washed with PBS, pulsed with DCFDA for 10 min at 
37°C, 5% CO2, and analyzed by FACScan cytofluorimeter 
using the CellQuest software. The percentage of positive 
cells determined over 10,000 events was analyzed on a 
FACScan cytofluorimeter using the CellQuest software.
Mitochondrial transmembrane potential (ΔΨm)
ΔΨm was evaluated by JC-1 staining. 5637 and 
T24 BC cells (4x104/ml), seeded into 24-well plates, were 
treated with sorafenib (20 μM) or vehicle for different 
times and then incubated for 10 min at room temperature 
with JC-1. JC-1 was excited by an argon laser (488 nm); 
green (530 nrn)/red (>570 nrn) emission fluorescence 
was collected simultaneously. Carbonyl cyanide 
chlorophenylhydrazone protonophore, a mitochondrial 
uncoupler that collapses ΔΨm was used as positive control 
(data not shown). Samples were analyzed by a FACScan 
cytofluorimeter using the CellQuest software; fluorescence 
intensity was expressed in arbitrary units on logarithmic 
scale.
Molecular docking analysis
Molecular docking analysis was performed on 
Linux Red Hat Pentium4 – based platform using Autodock 
Vina [57] and InsightII software (Release 2005, Accelrys 
Ltd., Cambridge, U.K). Human CB X-ray crystal structure 
(pdbID:1CSB) [58] was obtained from the Protein Data 
Bank [59]. Pdbqt three-dimensional structure files of 
sorafenib and pazopanib comparative drugs and CB 
were obtained by adding polar hydrogens and removing 
water from protein, and were submitted to Vina, setting 
a docking grid with a size of 60Å × 65Å × 50Å, centered 
at the position x = 21.18, y = -6.05, z = 38.08. Then, the 
most stable composite CB/TKI drug model was refined 
using Discover module of InsightII, minimizing all atoms 
as previously reported [59]. Docking module was used to 
calculate total intermolecular energy (ETotal = EElect + EVdW) 
and Ludi module was used to calculate LUDI Score and 
the related predicted equilibrium dissociation constants 
Kd by the standard equation LUDI Score = -100 × log10 
Kd and the Energy Estimate 3 [58]. PyMOL software 
(DeLano Scientific LLC, San Carlos, CA, 2009-10) was 
used to render all the output from InsightII and to calculate 
the distances of hydrogen bonds as measured between the 
hydrogen and its assumed binding partner.
Cathepsin B activity
CB proteolytic activity was measured in 5637 and 
T24 BC cells at 1, 3, 6 and 12 h after sorafenib (20 μM) 
treatment following the protocol described by Tchoupe and 
coworkers using the fluorogenic peptide Z-Arg-Arg-AMC 
at a final concentration of 50 μM. The mixture, containing 
5 μg of protein lysate, was incubated in 50 mM phosphate 
buffer pH 6.0, 1 mM EDTA and 2 mM dithiothreitol for 1 
h at 30 °C. The fluorescence of the hydrolyzed 7-amino-
4-methyl-coumarin (AMC, λexc=365 nm, λem=449 nm) 
was detected on a SpectraMax Gemini XPS microplate 
reader (Molecular Devices). In some experiments, CB 
activity was evaluated in T24 cells pretreated for 30 min 
with 0.25 mM of sodium orthovanadate and then treated 
for 1, 3 and 6 h with sorafenib (20 μM) [60].
Western blot
5637 and T24 BC cells, untreated or treated for 
different times with sorafenib (20 μM), vehicle or 
pretreated for 30 min with sodium orthovanadate (0.25 
mM), before the treatment with sorafenib (20 μM) for 24 
h, were lysed in lysis buffer (1M Tris pH 7.4, 1 M NaCl, 
10 mM EGTA, 100 mM NaF, 100 mM Na3V04, 100 mM 
phenylmethylsulfonyl fluoride, 2% deoxycholate, 100 mM 
EDTA, 10% Triton X-l00, 10% glycerol, 10% SDS, 0.1 
M Na4P207) containing protease inhibitor cocktail (Sigma-
Aldrich) by using a Mixer Mill MM300 (Qiagen, Hilden, 
Germany). Lysates were separated on SDS polyacrylamide 
gel and transferred onto Hybond-C extra membranes (GE 
Healthcare). Blots were incubated with blocking solution 
and the primary Ab anti-CB followed by the appropriate 
HRP-conjugated secondary Abs according to the specific 
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datasheet. In some experiments lysates coming from 
T24 BC cells treated for different times with (20 μM) 
sorafenib alone or in combination with bafilomycin A 
[27] or CA074Me were incubated with: anti-SHP-1, anti-
pSHP-1, anti-PTEN, anti-non pPTEN, anti-AKT, anti-
pAKT and anti-BID. In addition, we also evaluated the 
cytochrome c and CB in the cytosolic fraction of 5637 
and T24 cells. Briefly, untreated or sorafenib-treated 
cells for different times (1, 3 and 6 h) were washed in 
ice-cold PBS and the resulting pellet was resuspended 
in 0.12 ml of lysis buffer (20 mM HEPES), 10 mM 
KCl, 1.5 mM MgCl2, 1mM EDTA, 1 mM EGTA, 1 mM 
DTT and 0.1 mM PMSF) supplemented with protease 
inhibitor cocktail. After sitting on ice for 15 min, cells 
were disrupted by 60 times douncing in a mini-potter. 
The nuclei were pelletted at 1000g for 5 min at 4°C and 
the supernatants were separated and centrifuged for 40 
min at 80000g. Then, supernatants loaded onto a 12% 
SDS–PAGE were transferred and incubated with anti-
cytochrome c (0.5 µg/ml) or -CB (250 ng/mL) mAbs 
followed by HRP-conjugated anti-mouse (1:2000) Ab. 
GAPDH expression levels were used as loading control. 
The detection was performed using the LiteAblot ®PLUS 
or the LiteAblot ®TURBO (EuroClone, Milano, Italy) kits 
and densitometric analysis was carried out by evaluating 
three independent experiments by a Chemidoc using the 
Quantity One software (BioRad, Hercules, USA).
Immunoprecipitation (IP)
Cell lysates (300 μg) from T24 and 5637 BC 
cells, untreated or treated for 1 and 3 h with sorafenib 
(20 μM) or for 3 h with perifosine (0.5, 1 and 2.5 
μM), were immunoprecipitated using anti-CB mAb 
following the Immunoprecipitation Kit Dynabeads® 
Protein A instructions (Life Technologies, Monza, Italy). 
Immunoprecipitated samples were then applied on SDS-
PAGE, transferred, and blotted with anti-pTyr and with 
polyclonal anti-CB Abs according to the datasheet. As IP 
control, isotype-matched IgG was used. Detection was 
performed as described above.
Statistical analysis 
The statistical significance was determined by 
Student’s t-test and by one way ANOVA. No statistical 
significant difference was found between untreated and 
vehicle (DMSO)-treated cells or comparing different times 
of vehicle-treatment each other (data not shown).
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